The human answer comes first
What Ipamorelin changes and what it has not proved
Ipamorelin briefly raises growth hormone. Half the drug remained in men's blood after about 2 hours, but its only large human trial failed.
What Ipamorelin changes and where the proof ends
Ipamorelin is man-made and gives growth hormone a brief rise. The studies show a blood change, not a proven gain in sleep, strength, or recovery.
The drug prods a small gland below the brain, and growth hormone enters the blood. In early animal work, two other hormones barely changed [1].
Those were the stress hormone and the hormone used to make breast milk. Their steady levels were promising, but they did not prove the drug was safe.
Some people who use Ipamorelin for research report better sleep or less soreness. No fair trial gathered those reports, so they can't foretell your result.
Ipamorelin isn't approved medicine, and its human trial did no better than placebo, the look-alike treatment [3]. Long use has not been studied; Ipamorelin effects sets out the risks that could matter to your health.
What early Ipamorelin tests found in blood
Ipamorelin joins five amino acids. These are the building blocks found in proteins.
The drug reaches the growth gland by using part of the hunger system. In 1998, rat and pig tests compared it with GHRP-6, an older growth-hormone drug.
The comparison asked whether Ipamorelin caused fewer unwanted hormone changes. Growth hormone rose, but the two other hormones stayed nearly level [1].
The short test can't tell us what months of use would do. In 1999, eight healthy men in each group received Ipamorelin.
The men's growth-hormone reading peaked near 40 minutes. Half the drug remained at about 2 hours [2], yet neither result tells you whether the drug would help.
What Ipamorelin failed to do after bowel surgery
Only one Phase 2 trial, a middle-stage test in people, asked whether Ipamorelin helped patients. The result did not clearly favor the drug.
Researchers enrolled 114 adults who had undergone bowel surgery [3]. They put Ipamorelin into a vein and stopped within seven days.
Patients who got Ipamorelin ate sooner than those given placebo. The difference was small enough to be chance, so the trial failed its main test [3].
Researchers counted all illnesses and other unwanted events during the hospital stay [3]. Such trouble was common in both groups, and the brief test can't settle your long-term risk.
What Ipamorelin changed in rat bones and ferret weight
The favorable results came mostly from animals, not people. For 15 days, female rats got 18, 90, or 450 micrograms daily under the skin.
It takes 1 million micrograms to make a gram; these were still animal test amounts. They aren't directions for you.
Without Ipamorelin, rat bones grew 42 millionths of a meter each day. With it, they grew 44, 50, or 52 millionths a day [4].
Those were tiny changes in bone length, not proof of stronger bones or less pain. A blood sign linked with growth stayed level.
In 2024, sick ferrets got belly shots during cancer care. They lost about 24% less body weight, but Ipamorelin did not ease vomiting [5].
Rat and ferret findings can't foretell how your body would respond. Ipamorelin research explains what each animal test did and did not show.
What the Ipamorelin rules change for a patient
Ipamorelin is not FDA-approved for any illness or use. Its Phase 2 program, a middle-stage human test, missed the main bowel-recovery goal [3].
Sports bodies ban Ipamorelin at all times. Drug-testing labs can also find the drug in urine.
FDA's page current as of April 22, 2026 records the withdrawn Ipamorelin acetate nomination for pharmacies mixing medicine for individual patients (503A), with its safety concerns kept beside the drug. Ipamorelin acetate still sits on the Category 2 list for outsourcing facilities (503B). FDA has not explained how a patient-specific pharmacy should read the withdrawn request. That list covered drugs still being weighed for mixing by special pharmacies.
Removal made that pharmacy route harder; it did not make the drug legal or approved. FDA advisers met on October 29, 2024, and their meeting supplied no proof that Ipamorelin was safe or worked.